<DOC>
	<DOCNO>NCT00543244</DOCNO>
	<brief_summary>Hepatitis C virus ( HCV ) infection global health problem , may lead chronic hepatitis , cirrhosis , hepatic decompensation hepatocellular carcinoma ( HCC ) . Recently , treatment peginterferon alfa plus ribavirin become standard care patient chronic hepatitis C. While genotype 2 patient higher sustained virologic response ( SVR ) rate 80-90 % , genotype 1 patient generally low SVR rate 40-50 % . In contrast , genotype 1 Taiwanese patient superior SVR rate Western country . Despite overall improve response combination therapy , 75 % patient suffer treatment-related adverse event cost remain high , make individualized therapy paramount importance maximize treatment response minimize adverse event . HCV viral kinetics interferon-based therapy study recently evaluate patient response . Early viral kinetics show favorable SVR rate , make short treatment duration possible . However , different viral kinetics find ethnicity . Recently , pilot study evaluate viral kinetics 6 Taiwanese patient HCV infection receive peginterferon alfa plus ribavirin therapy show superior early viral kinetics Caucasian patient . Based favorable SVR rate treat Taiwanese patient chronic hepatitis C , investigator aim conduct large confirmatory study evaluate viral kinetics try define optimal treatment patient .</brief_summary>
	<brief_title>Early Prediction Successful Treatment Chronic Hepatitis C Virus Infection Taiwan</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) infection global health problem , may lead chronic hepatitis , cirrhosis , hepatic decompensation hepatocellular carcinoma ( HCC ) . [ 1,2 ] Recently , treatment peginterferon alfa plus ribavirin become standard care patient chronic hepatitis C. While genotype 2 patient higher sustained virologic response ( SVR ) rate 80-90 % , genotype 1 patient generally low SVR rate 40-50 % . [ 3-5 ] In contrast , genotype 1 Taiwanese patient superior SVR rate Western country . [ 6,7 ] Despite overall improve response combination therapy , 75 % patient suffer treatment-related adverse event cost remain high , [ 8,9 ] make individualized therapy paramount importance maximize treatment response minimize adverse event . HCV viral kinetics interferon-based therapy study recently evaluate patient response . [ 10-14 ] Early viral kinetics show favorable SVR rate , make short treatment duration possible . [ 15-18 ] However , different viral kinetics find ethnicity . [ 19-23 ] Recently , pilot study evaluate viral kinetics 6 Taiwanese patient HCV infection receive peginterferon alfa plus ribavirin therapy show superior early viral kinetics Caucasian patient . [ 24 ] Based favorable SVR rate treat Taiwanese patient chronic hepatitis C , investigator aim conduct large confirmatory study evaluate viral kinetics try define optimal treatment patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Treatment na√Øve Over 18 year old AntiHCV ( Abbott HCV EIA 2.0 , Abbott Diagnostic , Chicago , IL ) positive &gt; 6 month Detectable serum quantitative HCVRNA ( Cobas Amplicor HCV Monitor v2.0 , Roche Molecular Systems , Pleasanton , CA ) dynamic range 600~ &lt; 500,000 IU/ml Serum alanine aminotransferase level upper limit normal 6 month enrollment A liver biopsy consistent diagnosis chronic hepatitis C Anemia ( hemoglobin &lt; 13 gram per deciliter men &lt; 12 gram per deciliter woman ) Neutropenia ( neutrophil count &lt; 1,500 per cubic milliliter ) Thrombocytopenia ( platelet &lt; 90,000 per cubic milliliter ) Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Chronic alcohol abuse ( daily consumption &gt; 20 gram per day ) Decompensated liver disease ( ChildPugh class B C ) Serum creatinine level 1.5 time upper limit normal Autoimmune liver disease Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling contraception Unwilling receive serial blood sampling study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Pegylated interferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Virokinetics</keyword>
</DOC>